Orladeyo (berotralstat) Price in Pakistan

Orladeyo (berotralstat) is an oral medication developed for the prevention of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the extremities, face, gastrointestinal tract, and airway. Orladeyo offers a convenient once-daily oral prophylactic option for individuals managing this condition.

Mechanism of Action

Berotralstat functions as a plasma kallikrein inhibitor. In patients with HAE, uncontrolled activity of plasma kallikrein leads to excessive production of bradykinin, a peptide that increases vascular permeability and causes the characteristic swelling and pain of HAE attacks. By inhibiting plasma kallikrein, berotralstat reduces the generation of bradykinin, thereby preventing the onset of angioedema episodes.

Indications

Orladeyo is indicated for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in:

• Adults and adolescents aged 12 years and older.

It is important to note that Orladeyo is not intended for the treatment of acute HAE attacks. Patients should use appropriate rescue medications for acute episodes.

Contraindications

Orladeyo is contraindicated in patients with:

• Hypersensitivity: Known hypersensitivity to berotralstat or any of its excipients.

Patients should consult their healthcare provider for a comprehensive list of contraindications and to determine if Orladeyo is suitable for their condition.

Side Effects

Common side effects associated with Orladeyo include:

• Gastrointestinal Issues: Such as abdominal pain, diarrhea, and nausea.
• Headache: Reports of headaches have been noted during treatment.
• Fatigue: Some patients may experience tiredness or fatigue.

These side effects are generally mild to moderate in severity. Patients experiencing persistent or severe adverse effects should consult their healthcare provider.

Pricing in Different Countries

The price of Orladeyo varies across different countries. Below is a table summarizing the approximate monthly cost in select countries:

Prices are approximate and may vary based on pharmacy, insurance coverage, and local regulations.

Availability in Pakistan

As of now, specific pricing information for Orladeyo in Pakistan is not readily available. Patients in Pakistan interested in Orladeyo should consult with their healthcare providers or contact local pharmacies for information on availability and pricing. Additionally, international patient assistance programs may offer options to access medications not yet available locally.

Top Global Brands for Hereditary Angioedema (HAE) Management

Several pharmaceutical companies have developed treatments for HAE. Here are five notable brands:

1. Takeda Pharmaceutical Company: Known for Firazyr (icatibant) and Cinryze (C1 esterase inhibitor), used in the treatment and prevention of HAE attacks.
2. CSL Behring: Manufacturer of Berinert (C1 esterase inhibitor), utilized for acute HAE attack management.
3. Pharming Group N.V.: Producer of Ruconest (recombinant C1 esterase inhibitor), indicated for acute HAE attacks.
4. BioCryst Pharmaceuticals: Developer of Orladeyo (berotralstat), the first oral prophylactic treatment for HAE.
5. Shire (now part of Takeda): Offers Takhzyro (lanadelumab), a monoclonal antibody for preventing HAE attacks.